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Cytotoxicity of s-Receptor Ligands Is Associated
with Major Changes of Cellular Metabolism and
Complete Occupancy of the s-2 Subpopulation
Anna A. Rybczynska1, Rudi A. Dierckx1, Kiichi Ishiwata2, Philip H. Elsinga1, and Aren van Waarde1
1Nuclear Medicine and Molecular Imaging, University of Groningen Medical Center, University of Groningen, Groningen,
The Netherlands; and 2Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
Tumor cells can be selectively killed by application of s-ligands;
high concentrations (20–100 mM) are often required, however,
because either diffusion barriers must be passed to reach intra-
cellular sites or the entire s-receptor population should be occu-
pied to induce cell death. We measured receptor occupancies
associated with the cytotoxic effect and dose-dependent
changes of cellular metabolism in a tumor cell line. Methods:
C6 cells (rat glioma) were grown in monolayers and exposed to
(1)-pentazocine (s-1 agonist), AC915 (s-1 antagonist), rimcazole
(s-1/s-2 antagonist), or haloperidol (s-1/s-2 antagonist). Occu-
pancy of s-receptors by the test drugs was measured by study-
ing the competition of the test drugs with cellular binding of the
ligand 11C-SA4503. Metabolic changes were quantified by mea-
suring cellular uptake of 18F-FDG, 18F-FLT, 11C-choline, or 11C-
methionine. Cytotoxicity was assessed by cellular morphology
observation and cell counting after 24 h. Results: IC50 values
(drug concentrations resulting in 50% occupancy of the available
binding sites) of the test drugs for inhibition of cellular 11C-SA4503
binding were 6.5, 7.4, 0.36, and 0.27 mM for (1)-pentazocine,
AC915, rimcazole, and haloperidol, respectively. EC50 values
(dose required for a 50% reduction of cell number after 24 h)
were 710, 819, 31, and 58mM, for pentazocine, AC915, rimcazole,
and haloperidol, respectively. Cytotoxic doses of s-ligands were
generally associated with increased uptake of 18F-FDG, de-
creased uptake of 18F-FLT and 11C-choline, and little change in
11C-methionine uptake per viable cell. Conclusion: IC50 values
of the test drugs reflect their in vitro affinities to s-2 rather than
tos-1 receptors. Because cytotoxicity occurred at concentrations
2 orders of magnitude higher than IC50 values for inhibition of cel-
lular 11C-SA4503 binding, high (99%) occupancy of s-2 receptors
is associated with loss of cell viability. 18F-FLT, 11C-choline, and
18F-FDG responded most strongly to drug treatment and showed
changes corresponding to the cytotoxicity of the test compounds.
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Sigma receptors are unique proteins integrated in plasma
and endoplasmatic reticulum membranes of tissue derived
from immune, endocrine, and reproductive organs; kidney;
liver; and brain (1). s-receptors were initially considered as
a subtype of the opioid receptor but were later shown to be
unlike any other known neurotransmitter or hormone binding
site (2). After 30 y of extensive research, understanding
of the molecular cascade triggered by these transmembrane
proteins is still rudimentary (3). The 2 confirmed s-receptor
subtypes, 25-kD s-1 and 21.5-kD s-2 (4), are strongly
overexpressed in rapidly proliferating cells, for example, in
cancer cells from animals and humans, as compared with
healthy tissue (5–7). Although the sequence and partial
structure of the s-1 receptor are already established (8,9),
the existence of the s-2 receptor has been proven only
pharmacologically (10).
Many natural substances from plant extracts and newly
synthesized compounds were tested for s-receptor binding,
resulting in the availability of a broad range of s-receptor
ligands today (11). Interestingly, some of these compounds
were shown to be effective antineoplastic agents (12,13).
Later, in vitro (14–16) and in vivo (17,18) studies con-
firmed that s-ligands such as haloperidol and rimcazole
inhibit growth of both cultured cancer cells and in vivo
tumors, whereas they do not affect proliferation or survival
of the noncancer tissue (18). These studies highlighted the
potency of s-ligands to kill cancer cells with minimal side
effects. In most cell lines, including in C6 rat glioma, cell
death was observed only after administration of high con-
centrations (20–100 mM) of a s-1 receptor antagonist or a
s-2 receptor agonist (12,13). The reason for the require-
ment of high concentrations is unknown. Possibly biomem-
branes limit drug access to intracellular sites, or a high
fraction of the s-receptor population should be occupied to
kill tumor cells.
If a suitable radioligand for s-receptors is available,
dose-dependent occupancy of the receptor population by an
exogenous ligand can be assessed by performing a compe-
tition assay in intact cells. Measured occupancy values can
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be subsequently compared with the dose-dependent effects
of test drugs on cellular morphology and growth. The s-1
agonist SA4503, labeled with the positron emitter 11C, is
available for this purpose (19). We used C6 cells as an in
vitro model for the measurement of both s-receptor occu-
pancy and cytotoxic effects. This rat glioma cell line has
been used extensively in previous research because it
expresses high densities of both s-1 and s-2 receptors
(6). Rimcazole (s-1/s-2 receptor antagonist), haloperidol
(s-1/s-2 receptor antagonist), (1)-pentazocine (s-1 recep-
tor agonist), and AC915 (s-1 receptor antagonist) were
chosen as our model compounds because these drugs are
commercially available and are potent s-receptor ligands
(20–23). Several metabolic PET tracers, such as 18F-FDG,
39-deoxy-39-fluorothymidine (18F-FLT), 11C-choline, and
11C-methionine, are routinely produced in our laboratory.
These radiopharmaceuticals track changes in cellular
metabolism and may show altered uptake kinetics after
antitumor therapy (24). Thus, we could assess the dose-
dependent effects of s-ligands on cellular biochemistry.
The present study aimed to answer the following ques-
tions: Which concentrations of s-ligands should be admin-
istered to occupy a substantial fraction of the intracellular
receptor population and kill C6 cells? At which level of
receptor occupancy does cell death occur? Can PET tracers
detect any changes of cellular metabolism after s-ligand
binding? Which PET tracer is the most sensitive indicator
of reduced cellular viability?
MATERIALS AND METHODS
Culture Medium and Drugs
Dulbecco’s minimum essential medium (DMEM), fetal calf
serum (FCS), and trypsin were products of Invitrogen. AC915,
haloperidol, (1)-pentazocine, rimcazole, and trypan blue (0.4%
solution in phosphate-buffered saline) were purchased from
Sigma. AC915 was dissolved in water with slight heating, and
haloperidol and rimcazole were dissolved in ethanol. Stock solu-
tions of (1)-pentazocine were made in 0.1N hydrochloric acid.
Radiopharmaceuticals
11C-methionine, 11C-choline, 18F-FLT, and 18F-FDG were pre-
pared by standard procedures reported in the literature (25). 11C-
SA4503 was prepared by reaction of 11C-methyl iodide with the
appropriate 4-O-methyl precursor (26). Specific radioactivity at
the end of synthesis was greater than 22 TBq/mmol. All radio-
chemical purities were greater than 95%.
Cell Culture
C6 rat glioma cells obtained from the American Type Culture
Collection were grown as monolayers in DMEM (high glucose)
supplemented with 7.5% FCS in a humidified atmosphere of 5%
CO2/95% air at 37C. Before each experiment, the cells were
seeded in 12-well plates (Costar). An equal number of cells was
dispensed in each well and was supplied with 1.1 mL of DMEM
(high glucose) supplemented with 7.5% FCS.
Binding Studies
Binding studies were performed 48 h after seeding cells in
12-well plates, when confluency reached 80%290%. Various
concentrations of an unlabeled competitor (AC915, haloperidol,
(1)-pentazocine, or rimcazole; range, 1028 to 1023 M, in tripli-
cate) were dispensed to the culture medium in the wells. After
2 min, 4 MBq of 11C-SA4503 in less than 30 mL of saline
(containing 30% ethanol) were added to each well. After about
45 min of incubation, the medium was quickly removed, and the
monolayer was washed 3 times with phosphate-buffered saline.
Cells were then treated with 0.2 mL of trypsin. When the
monolayer had detached from the bottom of the well, 1 mL of
DMEM (high glucose) supplemented with 7.5% FCS was applied
to stop the proteolytic action. Cell aggregates were resolved by
repeated (at least 10-fold) pipetting of the trypsin/DMEM mixture.
Radioactivity in the cell suspension (1.2 mL) was assessed using a
g-counter (Compugamma 1282 CS; LKB-Wallac). A sample of
the suspension was mixed with trypan blue solution (1:1 v/v) and
used for cell counting. Cell numbers were manually determined,
using a phase-contrast microscope (Olympus), a Bu¨rker bright-
line chamber (depth, 0.1 mm; 0.0025 mm2 squares), and a hand-
tally counter.
Uptake of radioactivity normalized to the number of viable cells
was plotted against the logarithm of the dose of the competing drug
(in [M]). A 3-parameter curve (single-site competition model) was
fitted to these data, using the following equation:
Y 5 bottom1 ðtop 2 bottomÞ=ð11 10ðX 2 logIC50ÞÞ;
where IC50 is drug concentration resulting in 50% occupancy of
the available binding sites. GraphPad Prism (GraphPad Software)
was used for curve fitting and graphical presentation of data. Less
than 6% (in most wells , , 5%) of the administered tracer dose
was bound to the cells under these conditions.
Treatment with s-Ligands and Scoring of Morphologic
Effects
s-Ligands were administered 24 h after seeding cells in 12-well
plates when confluency had reached 40%245%. Final concentra-
tions in culture medium were 1, 3, 10, 30, and 100 (in some cases
also 300) times the IC50 value of the test drug for inhibition of
11C-SA4503 binding to cellular s-receptors (determined as de-
scribed above).
After 20–24 h of incubation with s-ligands, the cells were
monitored by phase-contrast microscopy. The effect of each
compound and concentration was scored relative to a control
receiving only solvent vehicle. Scoring was performed as de-
scribed previously (12). Experiments were performed in quadru-
plicate and repeated at least twice. Decreases of cell number after
drug treatment were quantified by harvesting and resuspending
cells in medium containing FCS, followed by manual counting as
described above.
Uptake Studies
Cellular uptake of metabolic PET tracers was determined after
24 h of treatment with either vehicle or a s-ligand. Experiments
were performed in quadruplicate and repeated at least twice. At
time zero, a PET tracer (4 MBq of 11C-methionine or 11C-choline
or 2 MBq of 18F-FDG or 18F-FLT in ,20 mL of saline) was added
to each well. After 45 min of incubation, cells were washed, and
cellular radioactivity was assessed as described above. Less than
1% (11C-methionine), 2% (18F-FDG), or 4% (11C-choline and
2050 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 49 • No. 12 • December 2008
18F-FLT) of the administered tracer dose was taken up by the cells
under these conditions.
Statistics
Differences between groups were examined using 1-way ANOVA.
A P value of less than 0.05 was considered statistically significant.
RESULTS
Receptor Occupancy
Curves describing competition between the test drugs
and the radioligand 11C-SA4503 for cellular s-receptors are
presented in Figure 1. The data were best fitted by a 1-site
competition model. IC50 values were either in the sub-
micromolar range (rimcazole, 0.36 mM; haloperidol, 0.27
mM) or in the micromolar range ((1)-pentazocine, 6.5 mM;
AC915, 7.4 mM).
Subtype Involvement
Table 1 lists literature values for the affinities (Kd) of the
test compounds to s-1 and s-2 receptors, determined by in
vitro binding assays using membrane fragments isolated
from rodent tissues. We observed much higher (60- to
1,500-fold) IC50 values in intact cells than known Kd values
at s-1 receptors, particularly in the case of AC915,
(1)-pentazocine, and haloperidol. However, IC50 values
of all test compounds corresponded closely to their Kd
values at s-2 receptors. Here, only minor (,3-fold) differ-
ences were observed. Therefore, IC50 values for inhibition
of 11C-SA4503 binding to intact cells corresponded to the
s-2 Kd rather than to the s-1 Kd of the test compounds.
Cytotoxicity
When the s-antagonists rimcazole, haloperidol, or AC915
were applied to C6 cells in culture, a dose-dependent growth
inhibition was observed after 24 h (Fig. 2). Low doses of the
test drugs did not affect cellular growth. Above a certain
threshold concentration (rimcazole, 20 mM; haloperidol,
25 mM; and AC915, 220 mM), a reduction in cell number
became apparent. EC50 values of the test compounds (effec-
tive concentrations resulting in 50% cell loss) were some-
what higher than the threshold for cytotoxicity (rimcazole,
31mM; haloperidol, 58mM; and AC915, 819mM). Virtually
complete cell deathwas observed after 24 h of treatment with
either 100 mM rimcazole or 150 mM haloperidol (Fig. 2).
Even 200 mM s-1 agonist (1)-pentazocine did not yet affect
cell division or viability. Here, the EC50 value for growth
inhibition was 710 mM.
Receptor Occupancy at Cytotoxic Dose
By comparing EC50 values of the test compounds with
their IC50 values for inhibition of 11C-SA4503 binding in
intact cells, s-receptor occupancies at cytotoxic doses of
the test drugs could be estimated, using the curves presen-
ted in Figure 1 or the formula for a single-site competition
model (see ‘‘Materials and Methods’’). Because EC50
values were about 2 orders of magnitude higher than the
corresponding IC50 values of the test drugs, cell death
appeared to be associated with virtually complete (i.e.,
99%) occupancy of the s-receptor population (Table 2).
Changes of Cellular Metabolism
The metabolic PET tracers that we used responded
differently to treatment of C6 cells with s-receptor ligands.
Cytotoxic doses of (1)-pentazocine, haloperidol, and
rimcazole were generally associated with increases of the
uptake of 18F-FDG, decreases of the uptake of 18F-FLT and
11C-choline, and little change of 11C-methionine uptake per
viable cell (Figs. 3–6).
Significant increases of 18F-FDG uptake were observed
only when a certain threshold concentration was exceeded.
The threshold dose for haloperidol and rimcazole was 10
mM but in the case of (1)-pentazocine was 30 mM (Fig. 3).
Maximal increases of 18F-FDG uptake (1111%, 1150%,
and1166% for haloperidol, rimcazole, and (1)-pentazocine,
respectively; all statistically significant) occurred at doses of
100 mM for haloperidol, 112 mM for rimcazole, and 660
mM for (1)-pentazocine. Higher doses of test drug could
FIGURE 1. Dose-dependent increase of cellular 11C-SA4503
binding by (1)-pentazocine (n), haloperidol (h), AC915 (;), and
rimcazole (,). Error bars indicate SEM. Specific binding was
calculated by subtracting nonspecific binding (i.e., residual
binding of radioligand in presence of highest dose of competing
drug) from total binding; it amounted to 70%280% of total
radioactivity uptake by cells.
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not be examined, because these resulted in a complete loss
of cells after 24 h. In contrast to the previously mentioned
s-ligands, AC915 in doses of up to 776 mM did not
increase cellular 18F-FDG uptake. A slight but statistically
significant decline (221%) of 18F-FDG uptake was ob-
served after incubation of cells with 220 mM AC915
(Fig. 3).
Treatment of C6 cells with rimcazole, (1)-pentazocine,
and haloperidol resulted in a dose-dependent depression of
18F-FLT uptake when drug concentrations exceeded thresh-
old values of 20, 50, and 80 mM, respectively (Fig. 4).
Strong and statistically significant depression of 18F-FLT
uptake was observed after a 24-h incubation of the cells
with 50 (rimcazole), 100 (haloperidol), or 645 mM ((1)-
pentazocine), to 6%, 17%, and 26% of the control, respec-
tively. In contrast to the previously mentioned s-ligands,
AC915 did not depress cellular 18F-FLT uptake but caused a
biphasic increase with a maximum occurring at a drug dose
of 74 mM (Fig. 4).
Cellular uptake of 11C-choline was depressed by all drug
treatments (Fig. 5). A decline occurred when the ligand
concentration of (1)-pentazocine and AC915 exceeded
70 mM (20 mM for haloperidol and 15 mM for rimcazole).
At concentrations of 650 ((1)-pentazocine), 711 (AC915),
or 45 mM (rimcazole), 11C-choline uptake was reduced
more than 80%, whereas a concentration of 60 mM for
haloperidol resulted in a 55% decline (Fig. 5).
No statistically significant changes of 11C-methionine
uptake occurred after 24 h of treatment of C6 cells with
(1)-pentazocine, haloperidol, or AC915 (Fig. 6). In con-
trast, rimcazole at concentrations greater than 10 mM
depressed uptake of the amino acid up to 40% (Fig. 6).
DISCUSSION
Competition Assays
11C-SA4503 has been reported to bind preferentially to
s-1 receptors (IC50, 17.4 nM at the s-1 and 1,784 nM at the
s-2 subtype (27); IC50, 4.7 nM at s-1 and 63.1 nM at s-2
receptors in a later study (28)). Therefore, we expected that
the potent s-1 selective ligands (1)-pentazocine and
AC915 would compete more efficiently (i.e., at lower
IC50 values) with cellular binding of 11C-SA4503 than
would the non–subtype-selective antagonists rimcazole and
haloperidol, which bind less potently to s-1 receptors. In
reality, however, rimcazole and haloperidol inhibited 11C-
SA4503 binding more potently (IC50 values, 0.36 and 0.27
mM, respectively) than did (1)-pentazocine and AC915
(IC50 values, 6.5 and 7.4 mM, respectively; Fig. 1). The
IC50 values corresponded closely to the s-2 Kd but not to
the s-1 Kd of the test compounds (Table 1).
This outcome of our competition assays can be under-
stood when the applied mass of 11C-SA4503 is considered.
TABLE 1
Binding of Test Compounds to s-Receptor Subtypes
Kd (nM)
IC50 for inhibition of
11C-SA4503
binding in C6 cells (nM)
IC50/Kd
Test drug s1-receptor s2-receptor s1-receptor s2-receptor
AC915 4.9 (rat liver) (22) .10,000 (rat liver) (22) 7,358 1,502 0.7
(1)-Pentazocine 7.0 (rat brain) (21);
5.5 (rat brain) (23)
2,470 (rat liver) (23);
1,923 (rat liver) (38)
6,495 928–1,181 2.6–3.4
Haloperidol 4.7 (rat brain) (39);
2.6 (rat brain) (23)
167 (rat liver) (23) 274 58–105 1.6
Rimcazole 690 (guinea pig brain) (20) 180 (guinea pig brain) (20) 356 0.5–0.8 2.0
FIGURE 2. Dose-dependent cell loss after 24 h of incubation
with (1)-pentazocine (n), haloperidol (h), AC915 (;), and
rimcazole (,). Note that x-axis scales of Figures 1 and 2 are
different. Error bars indicate SEM.
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To have acceptable count statistics even at high doses of a
competing drug after 60 min of incubation, it was necessary
to add 4 MBq of 11C-SA4503. At a specific radioactivity
of 22 TBq/mmol, this corresponds to a ligand mass of
0.2 nmol and a ligand concentration of 200 nM in each
well. The receptor Kd reported by Matsuno et al. (27)
predict that at this radioligand concentration, saturation of
s-1 receptors will occur and specific binding will be
observed mainly at the s-2 subtype.
Thus, the methods described in this article investigated
the relationship between cytotoxicity and s-2 receptor
occupancy, using the relatively low affinity of 11C-SA4503
for s-2 receptors. During in vivo scans with 11C-SA4503 in
humans, ligand concentrations in the 1028 or 1027 M range
will never be reached. Human SA4503-PET scans will,
therefore, reflect the regional distribution of s-1 rather than
s-receptors.
Cytotoxic Effects
According to the literature, relatively high doses of
s-antagonists (20–100 mM for rimcazole or haloperidol
(12,13)) are required for the killing of glioma cells. Our
TABLE 2
Receptor Occupancy at Cytotoxic Dose
Test drug
IC50 for inhibition of
11C-SA4503 binding
in C6 cells (mM)
EC50 for cell killing
(within 24 h; mM) EC50/IC50
Receptor
occupancy (%)
AC915 7.4 819 110 99.1
(1)-Pentazocine 6.5 710 109 99.1
Haloperidol 0.27 58 215 99.5
Rimcazole 0.36 31 86 98.9
FIGURE 3. Dose-dependent increase of cellular 18F-FDG
uptake by (1)-pentazocine (n), haloperidol (h), AC915 (;), and
rimcazole (,).
FIGURE 4. Dose-dependent inhibition of cellular 18F-FLT
uptake by (1)-pentazocine (n), haloperidol (h), AC915 (;),
and rimcazole (,).
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data confirm these reports (EC50, 31 mM for rimcazole and
58 mM for haloperidol; Fig. 2). Even higher doses of (1)-
pentazocine and AC915 were necessary to induce cell death
(EC50 values, 710 and 819 mM, respectively; Fig. 2). Such
high doses are not required because diffusion barriers limit
drug access to intracellular sites, for half-maximal occu-
pancy of the s-receptor population is reached already at
concentrations 100-fold lower than the EC50 for cell killing
(Table 2). Because we observed a decrease in cellular
viability only at drug concentrations 2 orders of magnitude
higher than the corresponding IC50 values for inhibition of
11C-SA4503 binding, our data indicate that cell death is
associated with virtually complete (.98%) occupancy of
the s-receptor population. Because 11C-SA4503 binding
occurred mainly at s-2 receptors under the conditions of
our assay, the data also suggest that cell death is induced
via the s-2 rather than via the s-1 subtype if the observed
cytotoxic effects are really mediated through s-receptors.
The curves describing cell loss after 24 h of treatment
with rimcazole and (1)-pentazocine have a steep slope,
indicating rapid cell killing when the drug dose exceeds a
sharp threshold concentration (Fig. 2). In contrast, cell death
induced by haloperidol and AC915 occurs more grad-
ually (Fig. 2). These different curve shapes may signify
that haloperidol and AC915 are partial agonists at s-2
receptors, whereas rimcazole and (1)-pentazocine are full
agonists. It is also possible that rimcazole and (1)-pentazocine
induce cell death via an additional mechanism, which occurs
in parallel and independently of occupancy of the s-2
receptor population. s-2 receptor–mediated cell death is
suggested by the fact that losses of cell viability always occur
at concentrations 2 orders of magnitude higher than the IC50
of the 4 test compounds for inhibition of 11C-SA4503 binding
to cellular s-2 receptors (Table 2). An additional mechanism
of cell death is suggested by the different shapes of the cell-
loss curves (Fig. 2) and by a cellular morphology that is
different after treatment of the cells with different s-ligands
(data not shown).
On the basis of these data, rimcazole appears to be the
most interesting compound for further study as an antican-
cer drug.
Metabolic Changes
In our in vitro model, we observed a large increase of
18F-FDG uptake after 24 h of incubation with s-receptor
ligands (Fig. 3). A similar increase of 18F-FDG uptake has
FIGURE 5. Dose-dependent inhibition of cellular 11C-choline
uptake by (1)-pentazocine (n), haloperidol (h), AC915 (;), and
rimcazole (,).
FIGURE 6. Dose-dependent inhibition of cellular 11C-methio-
nine uptake by (1)-pentazocine (n), haloperidol (h), AC915 (;),
and rimcazole (,). MET 5 methionine.
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been observed after some forms of chemo- and radiother-
apy in which the increase of uptake preceded cell death
(29,30). This increase may be a ‘‘metabolic flare’’ due to
increased energy consumption as a consequence of DNA
and membrane repair (29). Glucose transporters (glucose
transporter 1 and sodium-dependent glucose transporter 1)
are known to be overexpressed after various cellular stres-
ses, including hypoxia and heat shock (31). Rimcazole and
(1)-pentazocine interfered strongly with cellular 18F-FDG
uptake, whereas haloperidol and AC915 had smaller effects
on glucose metabolism (Fig. 3).
18F-FLT traces the salvage pathway of DNA synthesis.
The retention of this nucleoside is a measure of thymidine
kinase 1 activity within the cells (32,33). After treatment of
C6 cells with s-receptor ligands, we observed striking
decreases of 18F-FLT uptake. (1)-Pentazocine, rimcazole,
and haloperidol induced more than a 70% decline of
cellular 18F-FLT uptake at a dose 100 times greater than
the IC50 for inhibition of cellular 11C-SA4503 binding (Fig.
4). However, AC915 caused a less marked inhibition of
18F-FLT uptake, which is consistent with a smaller reduc-
tion of cellular proliferation (Fig. 4). The rank order of drug
effects on 18F-FLT uptake was the same as for 18F-FDG. In
the range of 3–30 times IC50 for inhibition of cellular
11C-SA4503 binding, AC915 induced a small increase of
18F-FLT uptake, which may reflect activation of repair
processes within the cells.
We tested 11C-choline uptake after treatment of C6 cells
with s-receptor ligands because total choline levels and
phosphatidylcholine synthesis are known to be elevated in
cancers of different origin, as compared with healthy tissue,
and are related to cellular proliferation. We observed the
expected strong decrease of 11C-choline uptake when cells
were treated with s-ligands (Fig. 5). Above the threshold
rimcazole concentration, the uptake of 11C-choline was
reduced rapidly, whereas (1)-pentazocine, AC915, and
haloperidol resulted in slower but progressive inhibition
of phospholipid metabolism. These results are consistent
with the fact that 11C-choline uptake by cancer cells is
related to the activity of the enzyme choline kinase (34),
which is generally directly proportional to the proliferative
status of the cell.
In contrast to 18F-FLT and 11C-choline, 11C-methionine
did not behave as a proliferation marker, and 11C-methionine
uptake per viable cell showed hardly any change (Fig. 6).
Thus, 11C-methionine appeared to trace cell number rather
than cellular viability after s-ligand treatment. The methyl
group of methionine, which contains the 11C label, is im-
plicated in many metabolic processes such as protein
synthesis, transmethylation, and polyamine synthesis. There-
fore, 11C-methionine has a complex metabolism, and uptake
of 11C-methionine by tumor cells may be a reflection of
several processes, which are affected differently by antican-
cer treatment, some being increased and others showing a
decrease (35). The lack of change in 11C-methionine uptake
may also indicate unaltered transport of this amino acid
through the cell membrane and slow transmethylation pro-
cesses (31).
Our data indicate that 18F-FLT and 11C-choline are the
tracers of choice for evaluation of the effects of s-ligands
on cellular proliferation. 18F-FDG may also provide useful
information, but 11C-methionine uptake is a reflection of
the cell number rather than the proliferation state.
Growth reduction of glioma cells and changes of cellular
metabolism were observed only at ligand concentrations
more than 30-fold higher than those required for 50%
occupancy of the s-2 receptor population. Strong decreases
of the number of viable cells occurred at drug concentra-
tions greater than or equal to 100-fold higher than the IC50
for inhibition of 11C-SA4503 binding. Thus, cell death was
associated with virtually complete (99%) occupancy of the
intracellular s-2 receptor pool.
Although high levels of receptor occupancy and drug
doses in the 1025 M range are required for rapid cell
killing, s-ligands appear to have potential as cancer ther-
apeutics for the following reasons. First, preliminary
studies, both from our own laboratory and from other insti-
tutions (18), have demonstrated that cell death is limited
to tumor cells and occurs only at much higher concentra-
tions in healthy normal cells. Adverse effects could be
further diminished by local application or selective drug
targeting. Second, significant inhibition of in vivo tumor
growth has been observed in a variety of tumor models in
response to s-ligands given systemically (17,18). Third,
because s-2 ligands trigger cell death both by caspase-
dependent and caspase-independent mechanisms, such
compounds may be suitable for treatment of a wide variety
of tumors, including caspase-deficient tumor types (36).
Last, subtoxic doses of s-ligands can be applied in com-
bination therapy and can potentiate the antitumor effects of
‘‘classic’’ cytostatic agents (36,37). Because of the thera-
peutic potential of s-ligands, radiopharmaceuticals for
s-receptors may be used not only as diagnostic imaging
agents but also as tools to assess s-receptor occupancy
during experimental tumor therapy.
CONCLUSION
In the present study, treatment of tumor cells with
cytotoxic doses of s-ligands resulted in strong increases
of the uptake of 18F-FDG and decreases of 18F-FLT and
11C-choline uptake per viable cell. Cell-specific uptake of
11C-methionine was largely unaltered under these conditions.
18F-FLT, 11C-choline, and 18F-FDG responded strongly to
drug treatment and were suitable tools in the evaluation of
the cytotoxicity of the test compounds. These PET tracers
may, therefore, be used in future in vivo studies.
REFERENCES
1. Su TP. Sigma receptors: putative links between nervous, endocrine and immune
systems. Eur J Biochem. 1991;200:633–642.
CYTOTOXICITY OF s-LIGANDS • Rybczynska et al. 2055
2. Quirion R, Chicheportiche R, Contreras PC, et al. Classification and nomen-
clature of phencyclidine and sigma binding receptor sites. Trends Neurosci.
1987;10:444–446.
3. Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric
disorders: focusing on the s1 receptor ligand. Expert Opin Ther Targets. 2008;
12:45–58.
4. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat
liver and kidney contain high densities of sigma 1 and sigma 2 receptors:
characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol.
1994;268:9–18.
5. Aydar E, Onganer P, Perrett R, Djamgoz MB, Palmer CP. The expression and
functional characterization of sigma s1 receptors in breast cancer cell lines.
Cancer Lett. 2006;242:245–257.
6. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a
wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55:408–413.
7. Thomas GE, Szucs M, Mamone JY, et al. Sigma and opioid receptors in human
brain tumors. Life Sci. 1990;46:1279–1286.
8. Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional
expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys
Res Commun. 1996;229:553–558.
9. Mei JF, Pasternak GW. Molecular cloning and pharmacological characterization
of the rat sigma1 receptor. Biochem Pharmacol. 2001;62:349–355.
10. Guitart X, Codony X, Monroy X. Sigma receptors: biology and therapeutic
potential. Psychopharmacology (Berl). 2004;174:301–319.
11. Newman AH, Coop A. Medicinal chemistry: new chemical classes and subtype-
selective ligands. In: Matsumoto RR, Bowen WD, Su TP, eds. Sigma Receptors:
Chemistry, Cell Biology and Clinical Implications. Berlin, Germany: Springer
Verlag; 2007:25–44.
12. Vilner BJ, de Costa BR, Bowen WD. Cytotoxic effects of sigma ligands: sigma
receptor-mediated alterations in cellular morphology and viability. J Neurosci.
1995;15:117–134.
13. Brent PJ, Pang GT. Sigma binding site ligands inhibit cell proliferation in
mammary and colon carcinoma cell lines and melanoma cells in culture. Eur
J Pharmacol. 1995;278:151–160.
14. Brent PJ, Pang G, Little G, Dosen PJ, Van Helden DF. The sigma receptor ligand,
reduced haloperidol, induces apoptosis and increases intracellular-free calcium
levels [Ca21]i in colon and mammary adenocarcinoma cells. Biochem Biophys
Res Commun. 1996;219:219–226.
15. Colabufo NA, Berardi F, Contino M et al. Antiproliferative and cytotoxic effects of
some s2 agonists and s1 antagonists in tumour cell lines. Naunyn Schmiedebergs
Arch Pharmacol. 2004;370:106–113.
16. Nordenberg J, Perlmutter I, Lavie G, et al. Anti-proliferative activity of
haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. Int
J Oncol. 2005;27:1097–1103.
17. Moody TW, Leyton J, John C. Sigma ligands inhibit the growth of small cell
lung cancer cells. Life Sci. 2000;66:1979–1986.
18. Spruce BA, Campbell LA, McTavish N, et al. Small molecule antagonists of the
sigma-1 receptor cause selective release of the death program in tumor and self-
reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004;
64:4875–4886.
19. Kawamura K, Ishiwata K, Tajima H, et al. In vivo evaluation of [11C]SA4503 as
a PET ligand for mapping CNS sigma1 receptors. Nucl Med Biol. 2000;27:
255–261.
20. Ferris RM, Harfenist M, McKenzie GM, Cooper B, Soroko FE, Maxwell RA.
BW 234U, (cis-9-(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochlor-
ide): a novel antipsychotic agent. J Pharm Pharmacol. 1982;34:388–390.
21. Cagnotto A, Bastone A, Mennini T. [3H](1)-pentazocine binding to rat brain
sigma 1 receptors. Eur J Pharmacol. 1994;266:131–138.
22. Maeda DY, Williams W, Bowen WD, Coop A. A sigma-1 receptor selective
analogue of BD1008: a potential substitute for (1)-opioids in sigma receptor
binding assays. Bioorg Med Chem Lett. 2000;10:17–18.
23. Ishiwata K, Kawamura K, Yajima K, QingGeLeTu, Mori H, Shiba K. Evaluation
of (1)-p-[11C]methylvesamicol for mapping sigma1 receptors: a comparison
with [11C]SA4503. Nucl Med Biol. 2006;33:543–548.
24. Van Waarde A, Been LB, Ishiwata K, Dierckx RA, Elsinga PH. Early response of
sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy:
an in vitro study in glioma cells. J Nucl Med. 2006;47:1538–1545.
25. Van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of
sigma-ligands and metabolic PET tracers for differentiating tumor from
inflammation. J Nucl Med. 2006;47:150–154.
26. Kawamura K, Elsinga PH, Kobayashi T, et al. Synthesis and evaluation of 11C- and
18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines
as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol.
2003;30:273–284.
27. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. Binding
properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur
J Pharmacol. 1996;306:271–279.
28. Lever JR, Gustafson JL, Xu R, Allmon RL, Lever SZ. s1 and s2 receptor binding
affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse. 2006;59:
350–358.
29. Slosman DO, Pugin J. Lack of correlation between tritiated deoxyglucose,
thallium-201 and technetium-99m-MIBI cell incorporation under various cell
stresses. J Nucl Med. 1994;35:120–126.
30. Furuta M, Hasegawa M, Hayakawa K, et al. Rapid rise in FDG uptake in an
irradiated human tumour xenograft. Eur J Nucl Med. 1997;24:435–438.
31. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine,
L-leucine, L-methionine and FDG in cultured cancer cells. J Nucl Med. 1996;37:
502–506.
32. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT
uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.
J Nucl Med. 2002;43:1210–1217.
33. Barthel H, Perumal M, Latigo J, et al. The uptake of 39-deoxy-39-
[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine
kinase 1 protein levels. Eur J Nucl Med Mol Imaging. 2005;32:257–263.
34. Yoshimoto M, Waki A, Obata A, Furukawa T, Yonekura Y, Fujibayashi Y.
Radiolabeled choline as a proliferation marker: comparison with radiolabeled
acetate. Nucl Med Biol. 2004;31:859–865.
35. Vaalburg W, Coenen HH, Crouzel C, et al. Amino acids for the measurement of
protein synthesis in vivo by PET. Int J Rad Appl Instrum B. 1992;19:227–237.
36. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic
pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer
Res. 2002;62:313–322.
37. Azzariti A, Colabufo NA, Berardi F, et al. Cyclohexylpiperazine derivative
PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth,
modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer.
Mol Cancer Ther. 2006;5:1807–1816.
38. Choi S-R, Yang B, Plo¨ssl K, et al. Development of a Tc-99m labeled sigma-2
receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med
Biol. 2001;28:657–666.
39. Barnes JM, Barnes NM, Barber PC, et al. Pharmacological comparison of
the sigma recognition site labelled by [3H]haloperidol in human and rat
cerebellum. Naunyn Schmiedebergs Arch Pharmacol. 1992;345:197–202.
2056 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 49 • No. 12 • December 2008
